Ignite Creation Date:
2025-12-24 @ 1:17 PM
Ignite Modification Date:
2026-01-04 @ 4:44 AM
Study NCT ID:
NCT02919995
Status:
COMPLETED
Last Update Posted:
2024-05-21
First Post:
2016-09-21
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of RPL554 in Patients With Cystic Fibrosis
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003550', 'term': 'Cystic Fibrosis'}], 'ancestors': [{'id': 'D010182', 'term': 'Pancreatic Diseases'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D030342', 'term': 'Genetic Diseases, Inborn'}, {'id': 'D009358', 'term': 'Congenital, Hereditary, and Neonatal Diseases and Abnormalities'}, {'id': 'D007232', 'term': 'Infant, Newborn, Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C512996', 'term': 'ensifentrine'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'brian.maurer@veronapharma.com', 'phone': '+19147675037', 'title': 'Brian Maurer', 'organization': 'Verona Pharma plc'}, 'certainAgreement': {'otherDetails': 'The Investigator shall not be permitted to present at symposia, national or regional professional meetings, nor publish in journals, theses or dissertations, or otherwise of their own choosing, methods and results of the Clinical Trial without the prior written approval of the Sponsor. Any such approved presentation or publication shall acknowledge the Sponsor as the sponsor of the Clinical Trial and owner of the results of the Clinical Trial.', 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': 'From informed consent through study completion, up to 52 days', 'eventGroups': [{'id': 'EG000', 'title': 'Higher Dose RPL554', 'description': 'Single dose of inhaled 6 mg RPL554\n\nRPL554: RPL554 suspension administered using a nebuliser', 'otherNumAtRisk': 9, 'deathsNumAtRisk': 9, 'otherNumAffected': 6, 'seriousNumAtRisk': 9, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Lower Dose RPL554', 'description': 'Single dose of inhaled 1.5 mg RPL554\n\nRPL554: RPL554 suspension administered using a nebuliser', 'otherNumAtRisk': 10, 'deathsNumAtRisk': 10, 'otherNumAffected': 6, 'seriousNumAtRisk': 10, 'deathsNumAffected': 0, 'seriousNumAffected': 1}, {'id': 'EG002', 'title': 'Placebo', 'description': 'Inhaled placebo dose\n\nPlacebo: Placebo solution administered using a nebuliser', 'otherNumAtRisk': 10, 'deathsNumAtRisk': 10, 'otherNumAffected': 3, 'seriousNumAtRisk': 10, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Forced expiratory volume decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 9, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Pulmonary function test decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Tachycardia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 9, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 10, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Drug hypersensitivity', 'stats': [{'groupId': 'EG000', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Immune system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Cough', 'stats': [{'groupId': 'EG000', 'numAtRisk': 9, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 10, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Nasal congestion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Rhinorrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 9, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Syncope', 'stats': [{'groupId': 'EG000', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Chest discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 9, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Abdominal pain lower', 'stats': [{'groupId': 'EG000', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Dry mouth', 'stats': [{'groupId': 'EG000', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 9, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Back pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Infective exacerbation of cystic fibrosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}, {'term': 'Oral candidiasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 9, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}], 'seriousEvents': [{'term': 'exacerbation of cystic fibrosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 10, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 10, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 19.1'}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'AUC by Dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Higher Dose RPL554', 'description': 'Single dose of inhaled 6 mg RPL554\n\nRPL554: RPL554 suspension administered using a nebuliser'}, {'id': 'OG001', 'title': 'Lower Dose RPL554', 'description': 'Single dose of inhaled 1.5 mg RPL554\n\nRPL554: RPL554 suspension administered using a nebuliser'}], 'classes': [{'categories': [{'measurements': [{'value': '7699', 'spread': '2965.7', 'groupId': 'OG000'}, {'value': '2342', 'spread': '1029.9', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Pre dose, 15 and 30 minutes and 1, 2, 4, 6, 8 and 24 hours post dose after each treatment', 'description': 'Area under the curve (AUC)', 'unitOfMeasure': 'pg*h/mL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'All randomised patients with blood sampling performed after at least one dose of RPL554 and with data sufficient to calculate pharmacokinetic parameters.'}, {'type': 'PRIMARY', 'title': 'Maximum Plasma Concentration After Each Dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Higher Dose RPL554', 'description': 'Single dose of inhaled 6 mg RPL554\n\nRPL554: RPL554 suspension administered using a nebuliser'}, {'id': 'OG001', 'title': 'Lower Dose RPL554', 'description': 'Single dose of inhaled 1.5 mg RPL554\n\nRPL554: RPL554 suspension administered using a nebuliser'}], 'classes': [{'categories': [{'measurements': [{'value': '828.3', 'spread': '256.1', 'groupId': 'OG000'}, {'value': '270.1', 'spread': '91.9', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Pre dose, 15 and 30 minutes and 1, 2, 4, 6, 8 and 24 hours post dose', 'description': 'Maximum plasma concentration (Cmax) after a single dose of RPL554', 'unitOfMeasure': 'pg/mL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'All randomised patients with blood sampling performed after at least one dose of RPL554 and with data sufficient to calculate pharmacokinetic parameters.'}, {'type': 'PRIMARY', 'title': 'Time to Maximum Plasma Concentration After Each Dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Higher Dose RPL554', 'description': 'Single dose of inhaled 6 mg RPL554\n\nRPL554: RPL554 suspension administered using a nebuliser'}, {'id': 'OG001', 'title': 'Lower Dose RPL554', 'description': 'Single dose of inhaled 1.5 mg RPL554\n\nRPL554: RPL554 suspension administered using a nebuliser'}], 'classes': [{'categories': [{'measurements': [{'value': '1.53', 'spread': '0.66', 'groupId': 'OG000'}, {'value': '1.33', 'spread': '0.62', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Pre dose, 15 and 30 minutes and 1, 2, 4, 6, 8 and 24 hours post dose', 'description': 'Time to maximum concentration (Tmax) after a single dose of RPL554', 'unitOfMeasure': 'hours', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'All randomised patients with blood sampling performed after at least one dose of RPL554 and with data sufficient to calculate pharmacokinetic parameters.'}, {'type': 'PRIMARY', 'title': 'Half Life for Each Dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Higher Dose RPL554', 'description': 'Single dose of inhaled 6 mg RPL554\n\nRPL554: RPL554 suspension administered using a nebuliser'}, {'id': 'OG001', 'title': 'Lower Dose RPL554', 'description': 'Single dose of inhaled 1.5 mg RPL554\n\nRPL554: RPL554 suspension administered using a nebuliser'}], 'classes': [{'categories': [{'measurements': [{'value': '10.14', 'spread': '3.1', 'groupId': 'OG000'}, {'value': '7.52', 'spread': '3.3', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Pre dose, 15 and 30 minutes and 1, 2, 4, 6, 8 and 24 hours post dose', 'description': 'Half life (t1/2) of RPL554', 'unitOfMeasure': 'Hours', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'All randomised patients with blood sampling performed after at least one dose of RPL554 and with data sufficient to calculate pharmacokinetic parameters.'}, {'type': 'SECONDARY', 'title': 'Peak FEV1 for Each Treatment', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Higher Dose RPL554', 'description': 'Single dose of inhaled 6 mg RPL554\n\nRPL554: RPL554 suspension administered using a nebuliser'}, {'id': 'OG001', 'title': 'Lower Dose RPL554', 'description': 'Single dose of inhaled 1.5 mg RPL554\n\nRPL554: RPL554 suspension administered using a nebuliser'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Inhaled placebo dose\n\nPlacebo: Placebo solution administered using a nebuliser'}], 'classes': [{'categories': [{'measurements': [{'value': '2.384', 'spread': '0.73', 'groupId': 'OG000'}, {'value': '2.247', 'spread': '0.72', 'groupId': 'OG001'}, {'value': '2.256', 'spread': '0.71', 'groupId': 'OG002'}]}]}], 'analyses': [{'pValue': '0.0196', 'groupIds': ['OG001', 'OG002'], 'paramType': 'Contrast ratio', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.038', 'ciLowerLimit': '1.007', 'ciUpperLimit': '1.07', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'OTHER'}, {'pValue': '0.0802', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Contrast ratio', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.024', 'ciLowerLimit': '0.997', 'ciUpperLimit': '1.052', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'OTHER'}, {'pValue': '0.3487', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Contrast ratio', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.986', 'ciLowerLimit': '0.957', 'ciUpperLimit': '1.017', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'Pre dose and 15 and 30 minutes and 1, 2 and 4 hours post dose after treatment', 'description': 'Maximum Forced expired volume in one second (FEV1) measured using spirometry', 'unitOfMeasure': 'Liters', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'All randomized patients with sufficient data collected after intake of study treatment to compute the pharmacodynamic parameters on at least two study visits.'}, {'type': 'SECONDARY', 'title': 'AUC FEV1(0-4h)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Higher Dose RPL554', 'description': 'Single dose of inhaled 6 mg RPL554\n\nRPL554: RPL554 suspension administered using a nebuliser'}, {'id': 'OG001', 'title': 'Lower Dose RPL554', 'description': 'Single dose of inhaled 1.5 mg RPL554\n\nRPL554: RPL554 suspension administered using a nebuliser'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Inhaled placebo dose\n\nPlacebo: Placebo solution administered using a nebuliser'}], 'classes': [{'categories': [{'measurements': [{'value': '2.313', 'spread': '0.73', 'groupId': 'OG000'}, {'value': '2.194', 'spread': '0.72', 'groupId': 'OG001'}, {'value': '2.133', 'spread': '0.73', 'groupId': 'OG002'}]}]}], 'analyses': [{'pValue': '0.0043', 'groupIds': ['OG001', 'OG002'], 'paramType': 'Contrast ratio', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.072', 'ciLowerLimit': '1.026', 'ciUpperLimit': '1.12', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'OTHER'}, {'pValue': '0.0109', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Contrast ratio', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.055', 'ciLowerLimit': '1.014', 'ciUpperLimit': '1.096', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'OTHER'}, {'pValue': '0.4306', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Contrast ratio', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.984', 'ciLowerLimit': '0.942', 'ciUpperLimit': '1.027', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'Pre dose and 15 and 30 minutes and 1, 2 and 4 hours post dose', 'description': 'Area under the curve for FEV1 over 4 hours measured using spirometry', 'unitOfMeasure': 'Liters', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'All randomized patients with sufficient data collected after intake of study treatment to compute the pharmacodynamic parameters on at least two study visits.'}, {'type': 'SECONDARY', 'title': 'AUC FEV1(0-6h)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Higher Dose RPL554', 'description': 'Single dose of inhaled 6 mg RPL554\n\nRPL554: RPL554 suspension administered using a nebuliser'}, {'id': 'OG001', 'title': 'Lower Dose RPL554', 'description': 'Single dose of inhaled 1.5 mg RPL554\n\nRPL554: RPL554 suspension administered using a nebuliser'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Inhaled placebo dose\n\nPlacebo: Placebo solution administered using a nebuliser'}], 'classes': [{'categories': [{'measurements': [{'value': '2.304', 'spread': '0.74', 'groupId': 'OG000'}, {'value': '2.188', 'spread': '0.73', 'groupId': 'OG001'}, {'value': '2.133', 'spread': '0.73', 'groupId': 'OG002'}]}]}], 'analyses': [{'pValue': '0.0064', 'groupIds': ['OG001', 'OG002'], 'paramType': 'Contrast ratio', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.065', 'ciLowerLimit': '1.021', 'ciUpperLimit': '1.11', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'OTHER'}, {'pValue': '0.0149', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Contrast ratio', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.049', 'ciLowerLimit': '1.011', 'ciUpperLimit': '1.089', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'OTHER'}, {'pValue': '0.466', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Contrast ratio', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.945', 'ciLowerLimit': '0.945', 'ciUpperLimit': '1.027', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'Pre dose and 15 and 30 minutes and 1, 2, 4 and 6 hours post dose', 'description': 'Area under the curve FEV1 over 6 hours measured using spirometry', 'unitOfMeasure': 'Liters', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'all randomized patients with sufficient data collected after intake of study treatment to compute the pharmacodynamic parameters on at least two study visits.'}, {'type': 'SECONDARY', 'title': 'AUC FEV1(0-8h)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Higher Dose RPL554', 'description': 'Single dose of inhaled 6 mg RPL554\n\nRPL554: RPL554 suspension administered using a nebuliser'}, {'id': 'OG001', 'title': 'Lower Dose RPL554', 'description': 'Single dose of inhaled 1.5 mg RPL554\n\nRPL554: RPL554 suspension administered using a nebuliser'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Inhaled placebo dose\n\nPlacebo: Placebo solution administered using a nebuliser'}], 'classes': [{'categories': [{'measurements': [{'value': '2.287', 'spread': '0.75', 'groupId': 'OG000'}, {'value': '2.185', 'spread': '0.74', 'groupId': 'OG001'}, {'value': '2.130', 'spread': '0.74', 'groupId': 'OG002'}]}]}], 'analyses': [{'pValue': '0.0093', 'groupIds': ['OG001', 'OG002'], 'paramType': 'Contrast ratio', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.061', 'ciLowerLimit': '1.017', 'ciUpperLimit': '1.107', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'OTHER'}, {'pValue': '0.0333', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Contrast ratio', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.042', 'ciLowerLimit': '1.004', 'ciUpperLimit': '1.082', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'OTHER'}, {'pValue': '0.3693', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Contrast ratio', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.982', 'ciLowerLimit': '0.941', 'ciUpperLimit': '1.024', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'OTHER'}], 'paramType': 'MEAN', 'timeFrame': 'pre dose and 15 and 30 minutes and 1, 2, 4, 6 and 8 hours post dose', 'description': 'Area under the curve for FEV1 over 8 hours measured using spirometry', 'unitOfMeasure': 'Liters', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'All randomised patients with sufficient data collected after intake of study treatment to compute the pharmacodynamic parameters on at least two study visits.'}, {'type': 'SECONDARY', 'title': 'FVC', 'timeFrame': 'Over 24 hours after treatment', 'description': 'Forced vital capacity (FVC) measured using spirometry', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants'}, {'type': 'SECONDARY', 'title': 'Breath Samples', 'timeFrame': '8 and 24 hours after treatment', 'description': 'Exhaled breath pH', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants'}, {'type': 'SECONDARY', 'title': 'Laboratory Safety Tests 1', 'timeFrame': 'Screening and end of study', 'description': 'Biochemistry panel parameters', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants'}, {'type': 'SECONDARY', 'title': 'Laboratory Safety Tests 2', 'timeFrame': 'Screening and end of study', 'description': 'Haematology panel parameters', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants'}, {'type': 'SECONDARY', 'title': 'Laboratory Safety Tests 3', 'timeFrame': 'Screening and end of study', 'description': 'Urinalysis measured by urine dipstick', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants'}, {'type': 'SECONDARY', 'title': 'Vital Signs 1', 'timeFrame': 'Over 8 hours after treatment', 'description': 'Pulse rate after 5 minutes supine', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants'}, {'type': 'SECONDARY', 'title': 'Vital Signs 2', 'timeFrame': 'Over 8 hours after treatment', 'description': 'Blood pressure after 5 minutes supine', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants'}, {'type': 'SECONDARY', 'title': 'ECG 1', 'timeFrame': 'Over 8 hours after treatment', 'description': 'Heart rate', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants'}, {'type': 'SECONDARY', 'title': 'ECG 2', 'timeFrame': 'Over 8 hours after treatment', 'description': 'QT interval', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants'}, {'type': 'OTHER_PRE_SPECIFIED', 'title': 'Sputum Rheology', 'timeFrame': '8 and 12 hours after treatment', 'description': 'Rheological analysis for interleukin 8, tumour necrosis factor alpha and myeloperoxidase', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants'}, {'type': 'OTHER_PRE_SPECIFIED', 'title': 'Sputum Measurements', 'timeFrame': '8 and 12 hours after treatment', 'description': 'Levels of inflammatory mediators', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Higher Dose RPL554/Lower Dose RPL554/Placebo', 'description': 'Single dose of inhaled 6 mg RPL554 in Period 1, Single inhaled dose of 1.5 mg RPL554 in Period 2, placebo in Period 3\n\nRPL554: RPL554 suspension administered using a nebuliser Placebo: Placebo solution administered using a nebuliser'}, {'id': 'FG001', 'title': 'Lower Dose RPL554/Placebo/Higher Dose RPL554', 'description': 'Single dose of inhaled 1.5 mg RPL554 in Period 1, single inhaled dose of placebo in Period 2, single inhaled dose of 6 mg RPL554 in Period 3\n\nRPL554: RPL554 suspension administered using a nebuliser Placebo: Placebo solution administered using a nebuliser'}, {'id': 'FG002', 'title': 'Higher Dose RPL554/Plaebo/Lower Dose RPL554', 'description': 'Single inhaled dose of 6 mg RPL554 in Period 1, single inhaled dose of placebo in Period 2, single inhaled dose of 1.5 mg RPL554 in Period 3\n\nRPL554: RPL554 suspension administered using a nebuliser Placebo: Placebo solution administered using a nebuliser'}, {'id': 'FG003', 'title': 'Lower Dose RPL554/Higher Dose RPL554/Placebo', 'description': 'Single inhaled dose of 1.5 mg RPL554 in Period 1, single inhaled dose of 6 mg RPL554 in Period 2, single inhaled dose of placebo in Period 3\n\nRPL554: RPL554 suspension administered using a nebuliser Placebo: Placebo solution administered using a nebuliser'}, {'id': 'FG004', 'title': 'Placebo/Higher Dose RPL554/Lower Dose RPL554', 'description': 'Single inhaled dose of placebo in Period 1, single inhaled dose of 6 mg RPL554 in Period 2, single inhaled dose of 1.5 mg RPL554 in Period 3\n\nRPL554: RPL554 suspension administered using a nebuliser Placebo: Placebo solution administered using a nebuliser'}, {'id': 'FG005', 'title': 'Placebo/Lower Dose RPL554/Higher Dose RPL554', 'description': 'Single inhaled dose of placebo in Period 1, single inhaled dose of 1.5 mg RPL554 in Period 2, single inhaled dose of 6 mg RPL554 in Period 3\n\nRPL554: RPL554 suspension administered using a nebuliser Placebo: Placebo solution administered using a nebuliser'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '2'}, {'groupId': 'FG004', 'numSubjects': '1'}, {'groupId': 'FG005', 'numSubjects': '2'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '2'}, {'groupId': 'FG004', 'numSubjects': '1'}, {'groupId': 'FG005', 'numSubjects': '1'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '1'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '1'}]}]}], 'preAssignmentDetails': '16 patients were screened; six patients failed screening. Patients had to discontinue long acting bronchodilators on the day prior to screening and short acting bronchodilators for 8 hours before all spirometry assessments'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}, {'value': '2', 'groupId': 'BG003'}, {'value': '1', 'groupId': 'BG004'}, {'value': '2', 'groupId': 'BG005'}, {'value': '10', 'groupId': 'BG006'}]}], 'groups': [{'id': 'BG000', 'title': 'Higher Dose RPL554/Lower Dose RPL554/Placebo', 'description': 'Single dose of inhaled 6 mg RPL554 in Period 1, single dose of inhaled 1.5 mg RPL554 in Period 2, single inhaled dose of placebo in Period 3\n\nRPL554: RPL554 suspension administered using a nebuliser Placebo: Placebo solution administered using a nebuliser'}, {'id': 'BG001', 'title': 'Lower Dose RPL554/Placebo/Higher Dose RPL554', 'description': 'Single dose of inhaled 1.5 mg RPL554 in Period 1, single dose of inhaled placebo RPL554 in Period 2, single dose of 6 mg RPL554 in Period 3\n\nRPL554: RPL554 suspension administered using a nebuliser Placebo: Placebo solution administered using a nebuliser'}, {'id': 'BG002', 'title': 'Higher Dose RPL554/Placebo/Lower Dose RPL554', 'description': 'Single dose of inhaled 6 mg RPL554 in Period 1, single dose of inhaled placebo in Period 2, single dose of inhaled 1.5 mg RPL554 in Period 3\n\nRPL554: RPL554 suspension administered using a nebuliser Placebo: Placebo solution administered using a nebuliser'}, {'id': 'BG003', 'title': 'Lower Dose RPL554/Higher Dose RPL554/Placebo', 'description': 'Single dose of inhaled 1.5 mg RPL554 in Period 1, single dose of inhaled 6 mg RPL554 in Period 2, single inhaled dose of placebo in Period 3\n\nRPL554: RPL554 suspension administered using a nebuliser Placebo: Placebo solution administered using a nebuliser'}, {'id': 'BG004', 'title': 'Placebo/Higher Dose RPL554/Lower Dose RPL554', 'description': 'Single dose of inhaled placebo in Period 1, single dose of inhaled 6 mg RPL554 in Period 2, single dose of inhaled 1.5 mg RPL554 in Period 3\n\nRPL554: RPL554 suspension administered using a nebuliser Placebo: Placebo solution administered using a nebuliser'}, {'id': 'BG005', 'title': 'Placebo/Lower Dose RPL554/Higher Dose RPL554', 'description': 'Single dose of inhaled placebo in Period 1, single dose of inhaled 1.5 mg RPL554 in Period 2, single dose of inhaled 6 mg RPL554 in Period 3\n\nRPL554: RPL554 suspension administered using a nebuliser Placebo: Placebo solution administered using a nebuliser'}, {'id': 'BG006', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Categorical', 'classes': [{'categories': [{'title': '<=18 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}]}, {'title': 'Between 18 and 65 years', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}, {'value': '2', 'groupId': 'BG003'}, {'value': '1', 'groupId': 'BG004'}, {'value': '2', 'groupId': 'BG005'}, {'value': '10', 'groupId': 'BG006'}]}, {'title': '>=65 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '1', 'groupId': 'BG005'}, {'value': '4', 'groupId': 'BG006'}]}, {'title': 'Male', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '1', 'groupId': 'BG004'}, {'value': '1', 'groupId': 'BG005'}, {'value': '6', 'groupId': 'BG006'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}]}, {'title': 'Asian', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}]}, {'title': 'Black or African American', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}]}, {'title': 'White', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}, {'value': '2', 'groupId': 'BG003'}, {'value': '1', 'groupId': 'BG004'}, {'value': '2', 'groupId': 'BG005'}, {'value': '10', 'groupId': 'BG006'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2017-10-19', 'size': 4883705, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_002.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2022-11-01T10:56', 'hasProtocol': True}, {'date': '2018-01-03', 'size': 345179, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_000.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2018-10-05T04:47', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'CROSSOVER'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 10}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2017-02-08', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2019-05', 'completionDateStruct': {'date': '2017-11-03', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-04-22', 'studyFirstSubmitDate': '2016-09-21', 'resultsFirstSubmitDate': '2018-12-07', 'studyFirstSubmitQcDate': '2016-09-27', 'lastUpdatePostDateStruct': {'date': '2024-05-21', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2018-12-07', 'studyFirstPostDateStruct': {'date': '2016-09-30', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2019-03-20', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2017-11-03', 'type': 'ACTUAL'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'Sputum Rheology', 'timeFrame': '8 and 12 hours after treatment', 'description': 'Rheological analysis for interleukin 8, tumour necrosis factor alpha and myeloperoxidase'}, {'measure': 'Sputum Measurements', 'timeFrame': '8 and 12 hours after treatment', 'description': 'Levels of inflammatory mediators'}], 'primaryOutcomes': [{'measure': 'AUC by Dose', 'timeFrame': 'Pre dose, 15 and 30 minutes and 1, 2, 4, 6, 8 and 24 hours post dose after each treatment', 'description': 'Area under the curve (AUC)'}, {'measure': 'Maximum Plasma Concentration After Each Dose', 'timeFrame': 'Pre dose, 15 and 30 minutes and 1, 2, 4, 6, 8 and 24 hours post dose', 'description': 'Maximum plasma concentration (Cmax) after a single dose of RPL554'}, {'measure': 'Time to Maximum Plasma Concentration After Each Dose', 'timeFrame': 'Pre dose, 15 and 30 minutes and 1, 2, 4, 6, 8 and 24 hours post dose', 'description': 'Time to maximum concentration (Tmax) after a single dose of RPL554'}, {'measure': 'Half Life for Each Dose', 'timeFrame': 'Pre dose, 15 and 30 minutes and 1, 2, 4, 6, 8 and 24 hours post dose', 'description': 'Half life (t1/2) of RPL554'}], 'secondaryOutcomes': [{'measure': 'Peak FEV1 for Each Treatment', 'timeFrame': 'Pre dose and 15 and 30 minutes and 1, 2 and 4 hours post dose after treatment', 'description': 'Maximum Forced expired volume in one second (FEV1) measured using spirometry'}, {'measure': 'AUC FEV1(0-4h)', 'timeFrame': 'Pre dose and 15 and 30 minutes and 1, 2 and 4 hours post dose', 'description': 'Area under the curve for FEV1 over 4 hours measured using spirometry'}, {'measure': 'AUC FEV1(0-6h)', 'timeFrame': 'Pre dose and 15 and 30 minutes and 1, 2, 4 and 6 hours post dose', 'description': 'Area under the curve FEV1 over 6 hours measured using spirometry'}, {'measure': 'AUC FEV1(0-8h)', 'timeFrame': 'pre dose and 15 and 30 minutes and 1, 2, 4, 6 and 8 hours post dose', 'description': 'Area under the curve for FEV1 over 8 hours measured using spirometry'}, {'measure': 'FVC', 'timeFrame': 'Over 24 hours after treatment', 'description': 'Forced vital capacity (FVC) measured using spirometry'}, {'measure': 'Breath Samples', 'timeFrame': '8 and 24 hours after treatment', 'description': 'Exhaled breath pH'}, {'measure': 'Laboratory Safety Tests 1', 'timeFrame': 'Screening and end of study', 'description': 'Biochemistry panel parameters'}, {'measure': 'Laboratory Safety Tests 2', 'timeFrame': 'Screening and end of study', 'description': 'Haematology panel parameters'}, {'measure': 'Laboratory Safety Tests 3', 'timeFrame': 'Screening and end of study', 'description': 'Urinalysis measured by urine dipstick'}, {'measure': 'Vital Signs 1', 'timeFrame': 'Over 8 hours after treatment', 'description': 'Pulse rate after 5 minutes supine'}, {'measure': 'Vital Signs 2', 'timeFrame': 'Over 8 hours after treatment', 'description': 'Blood pressure after 5 minutes supine'}, {'measure': 'ECG 1', 'timeFrame': 'Over 8 hours after treatment', 'description': 'Heart rate'}, {'measure': 'ECG 2', 'timeFrame': 'Over 8 hours after treatment', 'description': 'QT interval'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Cystic Fibrosis']}, 'descriptionModule': {'briefSummary': 'This study evaluates two doses of RPL554 and placebo in adult patients with cystic fibrosis. All patients receive all three treatments in a randomised sequence.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* 1\\. Sign an informed consent document indicating they understand the purpose of and procedures required for the study and are willing to participate in the study.\n\n 2\\. Male or female aged ≥18 years at the time of informed consent. Females of childbearing potential must have been using a consistent and reliable form of contraception (see Appendix 1) from the last menses before the first study treatment administration, and must commit to continue to do so during the study and for 3 months after the last dose of study treatment.\n\n 3\\. Have a 12-lead ECG recording at screening (Visit 1) and Visit 2 pre-dose showing the following:\n * Heart rate between 45 and 90 beats per minute\n * QT interval corrected for heart rate using Fridericia's formula (QTcF) interval ≤450 msec\n * QRS interval ≤120 msec\n * PR interval ≤220 msec\n * No clinically significant abnormality including morphology (e.g. left bundle branch block, atrioventricular nodal dysfunction, ST segment abnormalities) 4. Capable of complying with all study restrictions and procedures including ability to use the study nebuliser correctly.\n\n 5\\. Body mass index (BMI) between 18 and 30 kg/m2 (inclusive) with a minimum weight of 40 kg.\n\n 6\\. Patients with a genetic diagnosis of CF. 7. Spirometry at screening demonstrating an FEV1 ≥40% and ≤80% of predicted normal.\n\n 8\\. Capable of withdrawing from long acting bronchodilators1 until the end of the treatment period, and short acting bronchodilators for 8 hours prior to administration of study treatment.\n\n 9\\. Clinically stable CF in the 2 weeks prior to randomisation (Visit 2).\n\nExclusion Criteria:\n\n1. History of cirrhotic liver disease or portal hypertension.\n2. CF exacerbation requiring hospitalisation in the month prior to screening (Visit 1) or prior to randomisation (Visit 2).\n3. Use of oral or intravenous antibiotics (in additional to usual maintenance therapy) in the 2 weeks prior to screening (Visit 1) or randomisation (Visit 2).\n4. Other non-CF related respiratory disorders: Patients with a current diagnosis of active tuberculosis, lung cancer, sarcoidosis, sleep apnoea, known alpha-1 antitrypsin deficiency or other active pulmonary diseases.\n5. Previous lung resection or lung transplant.\n6. History of, or reason to believe a patient has, drug or alcohol abuse within the past 3 years.\n7. Received an experimental drug within 3 months or five half-lives, whichever is longer.\n8. Patients with a history of chronic uncontrolled disease including, but not limited to, cardiovascular (including arrhythmias), endocrine, active hyperthyroidism, neurological, hepatic, gastrointestinal, renal, haematological, urological, immunological or ophthalmic diseases that the Investigator believes are clinically significant.\n9. Documented cardiovascular disease: angina, recent or suspected myocardial infarction, congestive heart failure, a history of unstable, or uncontrolled hypertension, or has been diagnosed with hypertension in last 3 months.\n10. Has had major surgery, (requiring general anaesthesia) in the 6 weeks prior to screening (Visit 1) or will not have fully recovered from surgery, or planned surgery through the end of the study.\n11. Infection with nontuberculous mycobacteria, methicillin-resistant Staphylococcus aureus (MRSA), or Burkholderia species.\n12. Use of immune-suppression; long term use of prednisolone ≥10 mg/day.\n13. History of malignancy of any organ system within 5 years with the exception of localised skin cancers (basal or squamous cell).\n14. Clinically significant abnormal values for safety laboratory tests (haematology, biochemistry or urinalysis) at screening (Visit 1), as determined by the Investigator.\n15. A disclosed history or one known to the Investigator, of significant non-compliance in previous investigational studies or with prescribed medications.\n16. Requires oxygen therapy, even on an occasional basis.\n17. Pregnancy or lactation (female subjects only).\n18. Any other reason that the Investigator considers makes the patient unsuitable to participate. -"}, 'identificationModule': {'nctId': 'NCT02919995', 'briefTitle': 'A Study of RPL554 in Patients With Cystic Fibrosis', 'organization': {'class': 'INDUSTRY', 'fullName': 'Verona Pharma plc'}, 'officialTitle': 'A Phase IIa, Randomised, Double Blind, Placebo Controlled, Three Way Crossover Study to Assess the Pharmacokinetics of RPL554 Administered to Adult Patients With Cystic Fibrosis.', 'orgStudyIdInfo': {'id': 'RPL554-010-2015'}, 'secondaryIdInfos': [{'id': '2015-004263-36', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Higher Dose RPL554', 'description': 'Single dose of inhaled 6 mg RPL554', 'interventionNames': ['Drug: RPL554']}, {'type': 'EXPERIMENTAL', 'label': 'Lower dose RPL554', 'description': 'Single dose of inhaled 1.5 mg RPL554', 'interventionNames': ['Drug: RPL554']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo', 'description': 'Inhaled placebo dose', 'interventionNames': ['Drug: Placebo']}], 'interventions': [{'name': 'RPL554', 'type': 'DRUG', 'description': 'RPL554 suspension administered using a nebuliser', 'armGroupLabels': ['Higher Dose RPL554', 'Lower dose RPL554']}, {'name': 'Placebo', 'type': 'DRUG', 'description': 'Placebo solution administered using a nebuliser', 'armGroupLabels': ['Placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': 'CB23 3RE', 'city': 'Cambridge', 'country': 'United Kingdom', 'facility': 'Papworth Hospital', 'geoPoint': {'lat': 52.2, 'lon': 0.11667}}], 'overallOfficials': [{'name': 'Andres Floto', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Cambridge Centre for Medical Research, Papworth Hospital'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Verona Pharma plc', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'Cystic Fibrosis Trust', 'class': 'OTHER'}], 'responsibleParty': {'type': 'SPONSOR'}}}}